FDA Peptide Policy: Under Review, Not in Effect Yet

As of October 17, 2026, the day this article was written, the White House is reviewing a new FDA peptide policy filing. On October 14, 2026, the White House budget office logged an FDA notice titled Interim Access Policy for Compounding Using Certain Peptides. That filing is an administrative review step, not an active rule.

Neither the White House nor the FDA has released the policy text, a list of covered peptides, or a start date. On October 15, the Associated Press reported from two unnamed sources that the plan would temporarily cover some popular peptides, including BPC-157. That BPC-157 claim comes from anonymous sources rather than the public government record.

Nothing in the filing changes the status of BPC-157 today. BPC-157 remains not FDA-approved, and any compounded formulation offered through Promise is not FDA-approved.

What the October FDA peptide policy filing confirms

The confirmed facts sit in OIRA's regulatory review record at the White House Office of Information and Regulatory Affairs. OIRA reviews federal agency actions before publication, and the FDA submitted RIN 0910-ZD94 on October 14, 2026, at the "Notice" stage. The record lists "None" for the legal deadline, and OIRA's official under-review XML list dated October 16 still shows it under review.

An Alliance for Pharmacy Compounding statement on October 16 noted that the text is not public and the release timing is unknown.

An Associated Press report on October 15 cited two unnamed people who said the plan would temporarily cover some popular peptides, including BPC-157. A Reuters report the same day also confirmed that the filing itself provides no policy details.

Interim enforcement discretion vs. the 503A bulks list

The words "Interim Access Policy" point to an important distinction in federal compounding law. FDA's Section 503A bulk substances overview, current May 14, 2026, explains when a traditional 503A pharmacy may compound with a bulk ingredient. A bulk ingredient must comply with an applicable United States Pharmacopeia or National Formulary monograph, a public quality standard.

If no monograph exists, it must be a component of an approved drug; if neither condition applies, it must appear on the 503A bulks list. Every bulk substance also requires a valid certificate of analysis (a lab test report) and an FDA-registered manufacturer. Amending 21 CFR § 216.23 in the Electronic Code of Federal Regulations requires a proposed rule, public comment, and a final rule.

In that regulation, current through October 15, 2026, the positive list in paragraph (a) names six substances and omits BPC-157. An interim policy is different from changing that regulation. In its January 2025 interim policy guidance, the FDA described conditional enforcement discretion for specified Category 1 bulk substances.

Enforcement discretion means the FDA states it does not intend to take action if pharmacies meet specific conditions. That 2025 guidance is nonbinding, creates no legal rights, and leaves compounded drugs not FDA-approved. Because the October 2026 text is unpublished, the 2025 guidance cannot show what the new notice covers.

Today, FDA's significant safety risks page, current April 22, 2026, lists BPC-157 under withdrawn nominations. FDA says BPC-157 may pose a risk of an unwanted immune reaction for certain routes of administration. It also states that there is no, or only limited, safety-related information for the proposed routes.

In FDA's May 14, 2026 bulk categories document, BPC-157, TB-500 (a thymosin-beta-4 fragment), and KPV are absent from Categories 1, 2, and 3. That May 14 document places GHK-Cu in Category 1 except for injectable routes of administration. This limit concerns FDA's interim compounding policy, rather than describing any Promise product.

BPC-157, GHK-Cu, TB-500, and KPV are not FDA-approved. Standalone TB-500 and standalone KPV are coming soon to Promise as compounded medications, and the formulations Promise will offer are not FDA-approved.

Promise currently offers the KLOW blend (GHK-Cu, BPC-157, TB-500, and KPV) and the Wolverine blend (BPC-157 and TB-500). Both blends are compounded formulations that are not FDA-approved. A policy for one ingredient would not automatically cover a blend.

What the filing does not change for patients and doctors

An OIRA review filing is a real procedural step, but it puts no policy into effect today. A bounded Federal Register search through October 17, 2026 returned zero published documents matching the policy title or BPC-157 since July 19. The filing also follows an unresolved split over the July 2026 FDA peptide decision.

In an October 14 press release, the Center for Science in the Public Interest urged Acting Commissioner Kyle Diamantas to overrule the July panel. The panel voted to recommend six of seven peptides, whereas FDA's July 2026 briefing document proposed that none be included on the 503A list. Both advisory votes and advocacy letters remain separate from a final FDA decision.

The filing also adds no clinical trial data. FDA's May 11, 2026 evaluation of BPC-157 treated free base and acetate as separate substances lacking a monograph or approved-drug pathway.

It identified an older randomized, double-blind, placebo-controlled human ulcerative-colitis study reported only as a meeting abstract. Reviewers concluded there is insufficient clinical safety information to characterize the safety profile.

Two 2026 journal reviews reach similar conclusions. An August 2026 scoping review in The American Journal of Sports Medicine by Tewari and colleagues examined six sports-medicine compounds, including BPC-157. Across those six compounds, 67% of identified publications (about two in three papers) used preclinical animal models.

Tewari's team found few, mostly weakly controlled human studies. They said these compounds should not currently be recommended either to replace or to add to standard orthopaedic care.

An August 2026 review in Current Pain and Headache Reports by Luansritisakul and colleagues likewise noted that clinical evidence in humans is limited. They concluded that use should be guided by careful clinical judgment and ongoing evaluation of emerging evidence.

In practice, whether peptides are legal separates the prescribing decision from pharmacy rules. Regulatory status is one part of care, and a licensed provider may still prescribe — that decision is between you and your doctor. A prescription and a pharmacy's ingredient eligibility, sourcing, and compounding obligations remain separate requirements.

BPC-157 prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy. As FDA's compounding questions and answers page notes, compounded drugs are not FDA-approved and receive no premarket review for safety, effectiveness, or quality. Poor compounding, such as contamination or wrong strength, can lead to serious patient injury and death.

A prescription and a licensed pharmacy create lot traceability and clinical accountability. However, they do not eliminate compounding risk or supply missing trial evidence. At Promise, a licensed provider reviews every request and not everyone qualifies.

What to watch next

First, watch for OIRA to finish its review. Second, watch for FDA to publish the notice.

Only the published text will show which peptides, chemical forms (such as BPC-157 free base or acetate), pharmacy types, and conditions apply. Third, check the effective date inside any published notice, since publication and effectiveness do not always coincide. Fourth, watch separately for a proposed rule and public comment period to amend the 503A list in 21 CFR § 216.23(a).

Paragraph (d) of that rule also notes that list inclusion does not establish a compounded product's safety or efficacy. Until the FDA publishes actual policy text and operative dates, the federal rules on paper remain unchanged.